PDF(Pubmed)
Abstract：
UNASSIGNED: Early studies showed that the risks of mRNA vaccine-associated myocarditis and pericarditis are low but with substantial variation across studies. Study characteristics, ethnicity, vaccine types, dose intervals, and SARS-CoV-2 infection prevalence may influence the rates of myocarditis and pericarditis after mRNA vaccination in population-based studies.
UNASSIGNED: We comprehensively searched MEDLINE for relevant articles published before November 30, 2022. We also searched the websites of health authorities in several countries for unpublished surveillance data on myocarditis and pericarditis after mRNA vaccination. The outcome of interest was the incidence of myocarditis and pericarditis developed after mRNA vaccination for COVID-19.
UNASSIGNED: A total of 17 studies form 10 countries were included for review. We noted that considerable heterogeneity in study characteristics, including surveillance method, case definition, and observation period, may partially be responsible for the widely varied reported rates. Studies from countries that adopted active surveillance reported higher rates than those using passive surveillance. Compared to BNT162b2 vaccine, mRNA-1273 may have a higher risk of myocarditis only in young men after the second dose. Our comparison of sex-, age-, vaccine type-, and dose-specific rates of myocarditis across countries did not support the hypothesis that individuals with recent SARS-CoV-2 infection and young Asian males were at higher risk. We also could not find sufficient evidence to conclude whether extending the between-dose interval could reduce myocarditis incidence following mRNA vaccination.
UNASSIGNED: Differences in the study characteristics must be fully considered when comparing the risks of mRNA vaccine-related myocarditis and pericarditis in different countries.
UNASSIGNED: We comprehensively searched MEDLINE for relevant articles published before November 30, 2022. We also searched the websites of health authorities in several countries for unpublished surveillance data on myocarditis and pericarditis after mRNA vaccination. The outcome of interest was the incidence of myocarditis and pericarditis developed after mRNA vaccination for COVID-19.
UNASSIGNED: A total of 17 studies form 10 countries were included for review. We noted that considerable heterogeneity in study characteristics, including surveillance method, case definition, and observation period, may partially be responsible for the widely varied reported rates. Studies from countries that adopted active surveillance reported higher rates than those using passive surveillance. Compared to BNT162b2 vaccine, mRNA-1273 may have a higher risk of myocarditis only in young men after the second dose. Our comparison of sex-, age-, vaccine type-, and dose-specific rates of myocarditis across countries did not support the hypothesis that individuals with recent SARS-CoV-2 infection and young Asian males were at higher risk. We also could not find sufficient evidence to conclude whether extending the between-dose interval could reduce myocarditis incidence following mRNA vaccination.
UNASSIGNED: Differences in the study characteristics must be fully considered when comparing the risks of mRNA vaccine-related myocarditis and pericarditis in different countries.
摘要：
■早期研究表明，mRNA疫苗相关心肌炎和心包炎的风险很低，但在不同研究中差异很大。研究特点，种族,疫苗类型，剂量间隔,在以人群为基础的研究中,SARS-CoV-2感染率可能影响mRNA疫苗接种后心肌炎和心包炎的发病率.
■我们全面搜索了MEDLINE在2022年11月30日之前发表的相关文章。我们还在几个国家的卫生当局的网站上搜索了mRNA疫苗接种后未发表的心肌炎和心包炎的监测数据。感兴趣的结果是COVID-19mRNA疫苗接种后心肌炎和心包炎的发病率。
■共纳入10个国家的17项研究进行审查。我们注意到，研究特征存在相当大的异质性，包括监测方法，案例定义,和观察期，可能是报告率差异很大的部分原因。采用主动监测的国家的研究报告的比率高于采用被动监测的国家。与BNT162b2疫苗相比，mRNA-1273可能仅在第二次给药后的年轻男性中具有较高的心肌炎风险。我们对性别的比较-，年龄-,疫苗类型-，各国心肌炎的剂量特异性发病率和剂量特异性发病率均不支持以下假设:最近感染SARS-CoV-2的个体和年轻亚洲男性的风险较高.我们也没有找到足够的证据来得出结论，延长给药间隔是否可以降低mRNA疫苗接种后心肌炎的发病率。
■在比较不同国家的mRNA疫苗相关心肌炎和心包炎的风险时，必须充分考虑研究特征的差异。
■我们全面搜索了MEDLINE在2022年11月30日之前发表的相关文章。我们还在几个国家的卫生当局的网站上搜索了mRNA疫苗接种后未发表的心肌炎和心包炎的监测数据。感兴趣的结果是COVID-19mRNA疫苗接种后心肌炎和心包炎的发病率。
■共纳入10个国家的17项研究进行审查。我们注意到，研究特征存在相当大的异质性，包括监测方法，案例定义,和观察期，可能是报告率差异很大的部分原因。采用主动监测的国家的研究报告的比率高于采用被动监测的国家。与BNT162b2疫苗相比，mRNA-1273可能仅在第二次给药后的年轻男性中具有较高的心肌炎风险。我们对性别的比较-，年龄-,疫苗类型-，各国心肌炎的剂量特异性发病率和剂量特异性发病率均不支持以下假设:最近感染SARS-CoV-2的个体和年轻亚洲男性的风险较高.我们也没有找到足够的证据来得出结论，延长给药间隔是否可以降低mRNA疫苗接种后心肌炎的发病率。
■在比较不同国家的mRNA疫苗相关心肌炎和心包炎的风险时，必须充分考虑研究特征的差异。
